Capitainer is pleased to announce the opening of its new U.S. laboratory, miQro Lab Solutions, in Warwick, Rhode Island. This step reflects the company’s ambition to integrating its advanced self-sampling solutions into the U.S. healthcare system more rapidly. The establishment of the laboratory aims for quicker adoption of Capitainer’s efficient and user-friendly technologies.
The new miQro Lab Solutions, opening on January 17th, 2024, is a technologically advanced Capitainer-driven laboratory focusing on health and medical testing from Capitainer® qDBS sampling cards. It employs cutting-edge techniques for blood sample analysis and the detection and quantification of various elements and compounds.
Initially, the new miQro Lab Solutions laboratory will focus on clinical lab services, specializing in lead (Pb) screening, and plans to expand testing to other heavy metals, such as mercury, arsenic, and cadmium. The lab will leverage Capitainer’s products, known for its precision and efficiency in blood sampling.
The new laboratory marks a significant milestone in Capitainer’s expansion into the U.S. market, introducing its innovative technology for quantitative blood sampling from a finger-prick. CEO Christopher Aulin comments, “This marks a significant step in bringing our advanced dried blood sampling devices and expertise to the U.S. healthcare sector. Our new laboratory will use the Capitainer platform to validate various applications, making it simpler for our laboratory partners to set up services based on Capitainer products.”
Establishing the miQro Lab Solutions laboratory is a strategic step forward as it aims accelerate the adoption of Capitainer’s qDBS technology. By demonstrating the efficacy and versatility of the qDBS sampling cards, Capitainer aims to enhance market penetration of their technology. The laboratory is expected to play a pivotal role in showcasing the practical applications and benefits of qDBS to potential users and stakeholders in the healthcare industry.
About the miQro Lab Solutions laboratory
Capitainer’s Principal Scientist, Donald Chace, will serve as Lab Director, in partnership with cofounder and collaborative partner Tim Garrett, Professor at the University of Florida. The team at miQro Lab Solutions boasts over 50 years of combined experience in mass spectrometry and dried blood spot screening.
The laboratory is equipped with an ICP-MS (Inductively Coupled Plasma Mass Spectrometry) platform, a sophisticated technique used for detecting and quantifying trace elements and heavy metals in samples. In addition, the lab has access to LC-MS, a powerful analytical technique used to separate, identify, and quantify compounds in samples, commonly used in pharmacology, biochemistry, and environmental testing. The facility also has the capacity to rapidly expand its offering into clinical chemistry platforms, vital for analyzing bodily fluids, mainly blood and urine, in medical laboratories to diagnose and monitor diseases.
Visit capitainer.com/miqro to read more about the laboratory.
For more information, please contact:
Christopher Aulin, CEO
Phone: +46 (0)708 977577
Capitainer AB is a Swedish medtech company founded in 2016. Capitainer develops and sells intelligent solutions for self-sampling of blood, plasma, and urine. The company has developed unique technologies for collecting an exact amount of fluid and then allowing it to dry. The sample card can be sent with regular mail to laboratories without needing refrigerated transports or special packaging. The precision and accuracy in Capitainer’s samples are market-leading and perform on the same level as established pipetting methods. The products can be applied within several market segments, for instance, clinical biomarkers, therapeutic drug monitoring, genomics, drug development, drug abuse and doping testing, and R&D and clinical studies.